Dr. Powles on FDA Approval of Pembrolizumab Plus Axitinib in Advanced RCC
April 22nd 2019Thomas Powles, MBBS, MRCP, MD, director, Barts Cancer Institute, discusses the FDA approval of the combination of pembrolizumab (Keytruda) plus axitinib (Inlyta) for the frontline treatment of patients with advanced renal cell carcinoma (RCC).
Read More